Table 2.

AEs: the percentage and number (out of 28 evaluable patients) of patients with specified AEs (any grade and grades greater than 3 only) limited to possible or greater attribution

AEAny grade, % (n)Grade ≥3, % (n)
Neutrophil count decreased 85.7 (24) 75 (21) 
Platelet count decreased 60.7 (17) 60.7 (17) 
Anemia 50 (14) 32.1 (9) 
Febrile neutropenia 14.3 (4) 14.3 (4) 
Tumor lysis syndrome 14.3 (4) 14.3 (4) 
Hypokalemia 28.6 (8) 10.7 (3) 
White blood cell count decreased 21.4 (6) 10.7 (3) 
Lymphocyte count decreased 14.3 (4) 10.7 (3) 
Diarrhea 75 (21) 7.1 (2) 
Fatigue 71.4 (20) 7.1 (2) 
Upper respiratory infection 25 (7) 3.6 (1) 
Dysgeusia 42.9 (12) 0 (0) 
Nausea 42.9 (12) 0 (0) 
Headache 39.3 (11) 0 (0) 
Bruising 28.6 (8) 0 (0) 
Constipation 28.6 (8) 0 (0) 
Pruritus 28.6 (8) 0 (0) 
Abdominal pain 25 (7) 0 (0) 
Maculo-papular rash 25 (7) 0 (0) 
AEAny grade, % (n)Grade ≥3, % (n)
Neutrophil count decreased 85.7 (24) 75 (21) 
Platelet count decreased 60.7 (17) 60.7 (17) 
Anemia 50 (14) 32.1 (9) 
Febrile neutropenia 14.3 (4) 14.3 (4) 
Tumor lysis syndrome 14.3 (4) 14.3 (4) 
Hypokalemia 28.6 (8) 10.7 (3) 
White blood cell count decreased 21.4 (6) 10.7 (3) 
Lymphocyte count decreased 14.3 (4) 10.7 (3) 
Diarrhea 75 (21) 7.1 (2) 
Fatigue 71.4 (20) 7.1 (2) 
Upper respiratory infection 25 (7) 3.6 (1) 
Dysgeusia 42.9 (12) 0 (0) 
Nausea 42.9 (12) 0 (0) 
Headache 39.3 (11) 0 (0) 
Bruising 28.6 (8) 0 (0) 
Constipation 28.6 (8) 0 (0) 
Pruritus 28.6 (8) 0 (0) 
Abdominal pain 25 (7) 0 (0) 
Maculo-papular rash 25 (7) 0 (0) 

Only AEs with an overall incidence of 25% and/or with a grade ≥3 incidence of 10% are shown.

Close Modal

or Create an Account

Close Modal
Close Modal